Summary
Abbott Laboratories (ABT) announced the completion of the sale of its spine business to Zimmer, Inc. for approximately $360 million in cash on October 15, 2008. This divestiture is expected to generate a significant one-time pretax gain of at least $150 million for Abbott. The company plans to classify this gain as a specified item within its fourth quarter 2008 financial results. This transaction represents a strategic move by Abbott to focus on its core businesses. Investors should note the financial impact of this sale, particularly the substantial one-time gain, which will be recognized in the upcoming quarter. While the sale itself does not reflect ongoing operational performance, it highlights Abbott's active management of its portfolio and its commitment to enhancing shareholder value through strategic asset sales.
Key Highlights
- 1Abbott Laboratories completed the sale of its spine business to Zimmer, Inc.
- 2The transaction was valued at approximately $360 million in cash.
- 3Abbott anticipates a one-time pretax gain of at least $150 million from the sale.
- 4The gain is expected to be recognized as a specified item in the fourth quarter of 2008.
- 5This divestiture signals Abbott's focus on its core business areas.